InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-32.8%
Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Dubin Glenn, Director. Insider active across 1 company, notably C4 Therapeutics, Inc.. In total, 15 reports have been recorded. Activity tracked since 2 July 2021. The latest transaction was filed on 1 April 2024 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Declarations15 total
1,358 shares@ US$8.108.2% of flowCommon StockSEC:0001662579-24-000037:0
1,687 shares@ US$6.528.0% of flowCommon StockSEC:0001662579-24-000006:0
6,470 shares@ US$1.708.4% of flowCommon StockSEC:0001662579-23-000108:0
3,887 shares@ US$2.838.1% of flowCommon StockSEC:0001662579-23-000067:0
3,438 shares@ US$3.208.1% of flowCommon StockSEC:0001662579-23-000046:0
1,725 shares@ US$6.388.3% of flowCommon StockSEC:0001662579-23-000004:0
1,265 shares@ US$8.699.0% of flowCommon StockSEC:0001662579-22-000005:0
1,372 shares@ US$8.038.5% of flowCommon StockSEC:0001209191-22-040603:0
379 shares@ US$26.460.0049% mcap22.0% of flowCommon StockSEC:0001209191-22-023021:0
199 shares@ US$31.580.0030% mcap13.4% of flowCommon StockSEC:0001209191-22-003502:0
199 shares@ US$31.584.5% of flowCommon StockSEC:0001209191-22-003502
138 shares@ US$44.990.0029% mcap12.9% of flowCommon StockSEC:0001209191-21-059526:0
138 shares@ US$44.994.3% of flowCommon StockSEC:0001209191-21-059526
157 shares@ US$39.720.0028% mcap12.7% of flowCommon StockSEC:0001209191-21-052780:0
157 shares@ US$39.724.2% of flowCommon StockSEC:0001209191-21-052780
15 of 15 declarations
About Dubin Glenn
Glenn Dubin is a Board Member at C4 Therapeutics, Inc. As a board member, he participates in the governance of the company and provides his expertise to guide strategic decisions. His experience in the biopharmaceutical sector is beneficial for C4 Therapeutics.
